PRIME MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.66 USD | +3.74% |
|
+19.57% | -24.83% |
| May. 13 | JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating | MT |
| May. 10 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,609 | 817.2 | 770.1 | - | - |
| Enterprise Value (EV) 1 | 1,450 | 695.5 | 693.1 | 564.8 | 387.3 |
| P/E ratio | -4.43 x | -4.06 x | -3.97 x | -4.33 x | -4.4 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 150 x | 176 x | 86.5 x |
| EV / Revenue | - | - | 135 x | 129 x | 43.5 x |
| EV / EBITDA | -12.7 x | -3.42 x | -3.33 x | -2.31 x | -1.13 x |
| EV / FCF | -9.8 x | -3.99 x | -3.61 x | -2.72 x | -1.72 x |
| FCF Yield | -10.2% | -25% | -27.7% | -36.8% | -58.1% |
| Price to Book | 5.71 x | 6.06 x | 3.9 x | 3.78 x | 2.63 x |
| Nbr of stocks (in thousands) | 86,611 | 92,230 | 115,625 | - | - |
| Reference price 2 | 18.58 | 8.860 | 6.660 | 6.660 | 6.660 |
| Announcement Date | 3/9/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 5.142 | 4.384 | 8.903 |
| EBITDA 1 | - | -114.3 | -203.5 | -208.2 | -244 | -342.5 |
| EBIT 1 | - | -116.5 | -204.8 | -202.7 | -228.9 | -268.7 |
| Operating Margin | - | - | - | -3,941.72% | -5,221.85% | -3,018.6% |
| Earnings before Tax (EBT) 1 | -165.9 | -122.8 | -198.4 | -192.9 | -216.4 | -238.3 |
| Net income 1 | -165.4 | -142 | -198.1 | -193 | -216.4 | -237.1 |
| Net margin | - | - | - | -3,753.17% | -4,937.4% | -2,663.01% |
| EPS 2 | - | -4.190 | -2.180 | -1.679 | -1.539 | -1.515 |
| Free Cash Flow 1 | - | -147.9 | -174.1 | -192.2 | -207.6 | -225 |
| FCF margin | - | - | - | -3,738.24% | -4,735.61% | -2,527.72% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/7/22 | 3/9/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.591 | 1.63 | 0.1625 | 0.1625 | - | - |
| EBITDA 1 | - | - | -38.98 | - | - | -63.39 | -47.03 | -51 | -55 | -58 | - | - |
| EBIT 1 | -31.66 | -38.69 | -40.03 | -45.26 | -51.46 | -68.04 | -48.34 | -49.31 | -50.87 | -52.98 | -62.07 | -50.96 |
| Operating Margin | - | - | - | - | - | - | -8,179.53% | -3,025.05% | -31,306.68% | -32,602.46% | - | - |
| Earnings before Tax (EBT) 1 | - | -39.47 | -39.6 | -42.35 | -50.82 | -65.64 | -45.63 | -48.11 | -49.05 | -50.06 | -50.65 | -50.96 |
| Net income 1 | - | -40.6 | -39.4 | -42.38 | -50.71 | -65.64 | -45.76 | -48.12 | -49.06 | -50.09 | -50.65 | -50.96 |
| Net margin | - | - | - | - | - | - | -7,742.98% | -2,952.25% | -30,191.86% | -30,826.28% | - | - |
| EPS 2 | -1.610 | - | -0.4400 | -0.4700 | -0.5500 | -0.7200 | -0.4400 | -0.4098 | -0.4163 | -0.4111 | -0.3850 | -0.3850 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/22 | 3/9/23 | 5/11/23 | 8/7/23 | 11/3/23 | 3/1/24 | 5/10/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 159 | 122 | 77 | 205 | 383 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -148 | -174 | -192 | -208 | -225 |
| ROE (net income / shareholders' equity) | - | -177% | -88.2% | -137% | -145% | -88.2% |
| ROA (Net income/ Total Assets) | - | -42.9% | -71.5% | -78.6% | -65.3% | -64.2% |
| Assets 1 | - | 331.1 | 277.1 | 245.5 | 331.3 | 369.3 |
| Book Value Per Share 2 | - | 3.250 | 1.460 | 1.710 | 1.760 | 2.530 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 16.1 | 8.72 | 8.41 | 9.37 | 10.9 |
| Capex / Sales | - | - | - | 163.6% | 213.72% | 122.66% |
| Announcement Date | 3/7/22 | 3/9/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
6.42
USD
Average target price
14.6
USD
Spread / Average Target
+127.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.83% | 742M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- PRME Stock
- Financials Prime Medicine, Inc.